Fortress Biotech Q3 net revenue rises, driven by dermatology sales

By Reuters News


Overview

  • US biopharma firm's Q3 net revenue rose 9% yr/yr to $19.2 mln

  • Company posted Q3 net loss of $8.25 mln, reversing a profit last year

  • Fortress repaid $15 mln credit facility, leaving no parent-level debt


Outlook

  • Company did not provide specific financial guidance for future periods in its press release


Result Drivers

  • DERMATOLOGY SALES - Co said higher net revenue was mainly driven by increased sales of marketed dermatology products through Journey Medical

  • EMROSI PRESCRIPTIONS - Journey Medical reported approximately 40,000 Emrosi prescriptions in Q3, supported by improved reimbursement mix

  • ROYALTY INCOME - Co cited growing royalty income from ZYCUBO and UNLOXCYT as contributing to results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$8.25 mln

Q3 Income from Operations

-$7.19 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • Wall Street's median 12-month price target for Fortress Biotech Inc is $5.00, about 151.3% above its November 12 closing price of $1.99


Reuters Recommended Reads

  • Nov 12 - Journey Medical's Q3 revenue rises on Emrosi demand but misses estimates

  • Nov 12 - EyePoint Pharmaceuticals Q3 revenue falls, net loss widens

  • Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.